



WEDNESDAY, 14th NOVEMBER 2018 COMMENCING 09:30 AM
AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

Enclosure

1. **Welcome and introduction**

2. **Apologies**

3. **Declarations of interest**

4. **Minutes of previous meeting**

1/AWMSG/1118

To protect commercial confidentiality the following appraisals will be held in private

5. **Appraisal 1: Full Submission (WPAS)**
Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) for the treatment of adults infected with human immunodeficiency virus 1 without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir

2/AWMSG/1118
Appendices

The meeting will now open to the public for the committee decisions

6. **Chairman's report (verbal update)**

7. **Appraisal 2: Limited Submission**
Fosaprepitant (Ivemend®) for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy

3/AWMSG/1118
Appendices

8. **Appraisal 3: Limited Submission**
Tiotropium (Spiriva® Respimat®) as add-on maintenance bronchodilator treatment in patients aged 6 years to <18 years with severe asthma who experienced one or more severe asthma exacerbations in the preceding year

4/AWMSG/1118
Appendices

Date of next meeting – Wednesday, 12th December 2018 in Cardiff